A randomized, double-blind, comparison of radium-223 and placebo, in combination with abiraterone acetate and prednisolone, in castration-resistant metastatic prostate cancer: subgroup analysis of Japanese patients in the ERA 223 study.

MLA

Matsubara, Nobuaki, et al. “A Randomized, Double-Blind, Comparison of Radium-223 and Placebo, in Combination with Abiraterone Acetate and Prednisolone, in Castration-Resistant Metastatic Prostate Cancer: Subgroup Analysis of Japanese Patients in the ERA 223 Study.” International Journal of Clinical Oncology, vol. 25, no. 4, Apr. 2020, pp. 720–31. EBSCOhost, https://doi.org/10.1007/s10147-019-01589-6.

APA

Matsubara, N., Kimura, G., Uemura, H., Uemura, H., Nakamura, M., Nagamori, S., Mizokami, A., Kikukawa, H., Hosono, M., Kinuya, S., Krissel, H., Siegel, J., & Kakehi, Y. (2020). A randomized, double-blind, comparison of radium-223 and placebo, in combination with abiraterone acetate and prednisolone, in castration-resistant metastatic prostate cancer: subgroup analysis of Japanese patients in the ERA 223 study. International Journal of Clinical Oncology, 25(4), 720–731. https://doi.org/10.1007/s10147-019-01589-6

Chicago

Matsubara, Nobuaki, Go Kimura, Hiroji Uemura, Hirotsugu Uemura, Motonobu Nakamura, Satoshi Nagamori, Atsushi Mizokami, et al. 2020. “A Randomized, Double-Blind, Comparison of Radium-223 and Placebo, in Combination with Abiraterone Acetate and Prednisolone, in Castration-Resistant Metastatic Prostate Cancer: Subgroup Analysis of Japanese Patients in the ERA 223 Study.” International Journal of Clinical Oncology 25 (4): 720–31. doi:10.1007/s10147-019-01589-6.